FDA

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK #UK government #University of Sydney

This week in Drug Discovery (2 – 6 February) 

News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients?  The top stories:      Immunotherapy before surgery… Read More

#News

Back pain
#Biotech #Chronic low back pain #FDA #Persica Pharmaceuticals

Therapeutic approach could treat chronic low back pain 

A targeted therapeutic approach could effectively treat chronic low back pain (cLBP), data suggests.  The Phase Ib trial of PP353, developed by biotechnology company Persica Pharmaceuticals, demonstrated a clinically meaningful and durable reduction in pain and disability in patients with chronic low back pain and Modic Type 1 changes. Results have… Read More

#News

CT scans of the brain
#Alzheimer's #Biopharma #Clinical trial #Fast Track designation #FDA

Therapy could improve brain function in Alzheimer’s patients

An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows.  Valiltramiprosate, which received Fast Track designation from the US Food and Drug Administration (FDA) in 2017, is an investigational oral agent being evaluated as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease… Read More

#News

REGENXBIO
#Advanced Therapies #Adverse event #FDA #Gene therapy #Hunter Syndrome #Phase I trial #REGENXBIO

FDA pauses REGENXBIO’s gene therapies following tumour discovery

The US Food and Drug Administration (FDA) has placed a clinical hold on REGENXBIO’s investigational gene therapy, RGX-111, for the treatment of MPS I, following a single case of neoplasm (intraventricular CNS tumour) in a participant treated in its Phase I/II study.  The FDA also placed a clinical hold on… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Brain cancer #FDA #Gene therapy #Oncology #Phase I trial #Siren Biotechnology

FDA clears first cancer gene therapy for trials

The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial.  The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with recurrent high-grade glioma.  … Read More

#Cancer Research #Editor's Choice #News #Regulatory

#FDA #Investigational New Drug (IND) #Melanoma #Scancell Holdings

FDA clears IND application for melanoma treatment 

The US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a registration Phase III trial of iSCIB1+ Immunobody in advanced melanoma.  The application, submitted by biotechnology company Scancell Holdings, has been cleared with progression free survival as the agreed surrogate endpoint.  Scancell has completed the 140-patient SCOPE Phase II, open-label, multi-centre… Read More

#News #Regulatory

Female medical researcher
#BioXcel Therapeutics #Bipolar #FDA #Schizophrenia

sNDA application submitted for agitation drug 

Biopharmaceutical company BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for agitation treatment Igalmi.  Igalmi (dexmedetomidine) is a prescription medicine used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I and II in adults.   In April 2022, Igalmi was approved by the FDA as… Read More

#News #Regulatory

Gene therapy
#FDA #Gene therapy #Orphan drugs

FDA grants orphan drug designation to MMA treatment 

The US Food and Drug Administration (FDA) has granted orphan drug designation to a treatment for methylmalonic acidaemia (MMA).  GENE202, developed by biotechnology company Genespire, is an in vivo off-the-shelf gene therapy which harnesses the company’s Immune Shielded Lentiviral Vector (ISLV) platform to treat paediatric patients affected by genetic diseases.  GENE02, which has also been granted orphan drug… Read More

#News #Regulatory

#Awards #FDA #University of California San Diego

CIRM awards $7.4m for novel Freidreich’s ataxia therapy 

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a first-of-its-kind stem cell-based gene therapy for Friedreich’s ataxia.  The funding, awarded to a team at the University of California San Diego, will help researchers complete the final steps required by federal regulators before they… Read More

#News

AI
#Artificial intelligence (AI) #Drug discovery #European Medicines Agency #FDA

EMA and FDA set common principles for AI in drug development

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly identified 10 principles for good artificial intelligence (AI) practice in the medicines lifecycle.  The principles give broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research… Read More

#Editor's Choice #Editor's Pick #News #Regulatory

T cells
#Advanced Therapies #Atara #Cell and gene therapy #Cell therapy #FDA #Pierre Fabre Laboratories

FDA rejects second application for off-the-shelf T-cell therapy

The US Food and Drug Administration (FDA) said it is unable to approve the Atara Biotherapeutics’ off-the-shelf" allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) based on the company’s Biologics License Application (BLA).  The regulator ruled that the single arm ALLELE trial, which Atara’s says was previously confirmed by the FDA as adequate… Read More

#News #Regulatory

FDA headquarters
#FDA #Sentynl Therapeutics

FDA approves first ever Menkes disease therapy 

The US Food and Drug Administration (FDA) has approved the first and only therapy for Menkes disease.  Zycubo (copper histidinate), developed by US biopharmaceutical company Sentynl Therapeutics, is a subcutaneous injectable formulation given daily to deliver elemental copper to the body.  In a pooled analysis of two open label, single-arm… Read More

#News #Regulatory

Screening patient for AMD
#AMD #Complement Therapeutics #FDA #Geographic atrophy

FDA fast tracks geographic atrophy treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for a treatment for  geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  CTx001, developed by biotechnology company Complement Therapeutics, is a novel adeno-associated virus (AAV)-based gene therapy designed to deliver a truncated version of Complement Receptor 1 (mini-CR1). The fast-tracked therapy has… Read More

#News #Regulatory

#FDA #Investigational New Drug (IND) #Leukaemia #Lymphoma

FDA grants IND clearance to novel BTK degrader 

A novel treatment for relapsed/refractory B-cell malignancies has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA).  APG-3288, developed by biopharmaceutical company Ascentage Pharma, is a novel next-generation BTK-targeted protein degrader. The candidate is designed to induce rapid, potent, highly selective, and sustained degradation of both wild-type BTK… Read More

#News #Regulatory

#ALS #Fast Track designation #FDA

FDA grants Fast Track Designation to ALS treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a first-in-class vectorised antibody for the treatment of amyotrophic lateral sclerosis (ALS).  VTx-002, developed by biotechnology company VectorY Therapeutics, targets TDP-43 pathology, which drives up to 97% of ALS cases.  Fast Track is a process designed to facilitate the development and expedite the review of drugs… Read More

#News #Regulatory

Eye
#Advanced Therapies #FDA #Gene editing #Gene therapy #GenEditBio #Genetic diseases #Ophthalmology #Phase I trial

GenEditBio gets green light for in vivo genome-editing programme

The US Food and Drug Administration (FDA) has cleared GenEditBio to initiate Phase I/II CLARITY trial activities for its lead in vivo genome-editing programme GEB-101 for TGFBI corneal dystrophy.  The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients… Read More

#News #Regulatory #Trending News